Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INVO Fertility ( (IVF) ) has shared an announcement.
On January 28, 2026, INVO Fertility entered into a warrant inducement agreement with an institutional investor, under which the investor agreed to immediately exercise previously issued December 3, 2025 warrants for 4,733,728 shares at a reduced exercise price of $1.59 per share, generating approximately $7.5 million in gross proceeds before fees and expenses, and on January 30, 2026 the company issued new unregistered warrants for 9,467,456 additional shares at the same exercise price. In connection with the transaction, which Maxim Group LLC advised as exclusive lead warrant solicitation agent, INVO Fertility committed to register the resale of the new warrant shares, accepted restrictions on additional share or variable-rate financings for a defined period, and made the new warrants’ exercisability and five-and-a-half-year term contingent on future shareholder approval, underscoring both its reliance on equity-linked financing and the potential dilution and capital-structure implications for existing shareholders.
The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility Inc. is a healthcare services company focused on the fertility market, with a strategy centered on building, acquiring and operating fertility clinics, including INVO Centers dedicated to the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell medical device, as well as profitable U.S.-based in vitro fertilization (IVF) clinics. The company also sells and distributes INVOcell to third-party fertility clinics, promoting a lower-cost, more intimate assisted reproductive technology alternative that it believes can deliver results comparable to traditional IVF at a fraction of the cost and with greater effectiveness than intrauterine insemination.
Average Trading Volume: 7,143,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.87M
See more data about IVF stock on TipRanks’ Stock Analysis page.